Проблемы резистентности бактерий к антибиотикам и пути их решения в урологической практике

##plugins.themes.bootstrap3.article.sidebar##

PDF (Русский)
Published: Dec 20, 2016
DOI: https://doi.org/10.30841/2307-5090.4(59).2016.104362

##plugins.themes.bootstrap3.article.main##

І. Г. Березняков
Харьковская медицинская академия последипломного образования, Ukraine

##plugins.themes.bootstrap3.article.details##

How to Cite
Березняков, І. Г. (2016). Проблемы резистентности бактерий к антибиотикам и пути их решения в урологической практике. Health of Man, (4(59), 71–76. https://doi.org/10.30841/2307-5090.4(59).2016.104362
Issue
No. 4(59) (2016)
Section
Urology
Copyright (c) 2020 І. Г. Березняков

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.

References

Amyes S.G.B. Antimicrobial Chemotherapy. New York: Oxford University Press, 2010.

Березняков И.Г. Краткий справочник по эмпирическому использованию антибиотиков с лечебной и профилактической целью. Киев: Корпорация Артериум, 2014. 200 с.

Schultsz C., Geerlings S. Plasmid mediated resistance in Enterobacteriaceae. Changing landscape and implications for therapy. Drugs 2012; 72 (1): 1–16.

Палагин И.С., Сухорукова М.В., Дехнич А.В., и др., исследовательская группа «ДАРМИС». Современное состояние антибиотикорезистентности возбудителей внебольничных инфекций мочевых путей в России: результаты исследования «ДАРМИС» (2010–2011). Клин. микробиол. антимикроб. химиотер. 2012; 14 (4): 280–302.

Палагин И.С., Сухорукова М.В., Дехнич А.В., и др., исследовательская группа «ДАРМИС». Осложненные внебольничные инфекции мочевых путей у взрослых пациентов в России. Клин. микробиол. антимикроб. химиотер. 2014; 16 (1): 39–56.

The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for interpretation of MICs and zone diameters. Version 3.0, 2013. (http://www.eucast.org).

Ambler R.P., Meadway R.J. Chemical structure of bacterial penicillinases. Nature 1969; 222: 24–6.

Bush K., Jacoby G.A. Updated functional classification of blactamases. Antimicrob. Agents Chemother. 2010;54 (3): 969–76.

Зайцев А.А., Колобанова Е.В., Синопальников А.И. Внебольничные инфекции дыхательных путей: место «защищенных» аминопенициллинов. Леч. врач 2008; (5): 75–79.

Jacoby G.A. AmpC b lactamases. Clin. Microbiol. Rev. 2009; 22: 161–182.

Jacoby G.A., Mills D.M., Chow N. Role of b lactamases and porins in resistance to ertapenem and other b lactams in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2004; 48: 3203–3206.

Rodrнguez Martнnez J.M., Poirel L., Nordmann P. Extended spectrum cephalosporinases in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2009; 53: 1766–1771.

Mammeri H., Nordmann P., Berkani A., Eb F. Contribution of extended spectrum AmpC (ESAC) β-lactamases to carbapenem resistance in Escherichia coli. FEMS Microbiol. Lett. 2008; (282): 238–240.

Paterson D.L., Bonomo R.A. Extended spectrum beta lactamases: a clinical update. Clin. Microbiol.Rev. 2005; 18 (4): 657–86.

Pitout J.D.D. Infections with extended spectrum β lactamase producing Enterobacteriaceae. Changing epidemiology and drug treatment choices. Drugs 2010; 70 (3): 313–333.

Pitout J.D.,Nordmann P., Laupland K.B., et al. Emergence of Enterobacteriaceae producing extended spectrum beta lactamases (ESBLs) in the community. J. Antimicrob. Chemother. 2005; 56 (1): 52–9.

Livermore D.M., Patterson D.L. Pocket guide to extended spectrum b lactamases in resistance. London: Current Medicine Group Ltd., 2006.

Schwaber M.J., Carmeli Y. Mortality and delay in effective therapy associated with extended spectrum beta lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta analysis. J. Antimicrob. Chemother. 2007; 60 (5): 913–20.

Березняков И.Г. Клиническое значение выработки β-лактамаз и подходы к решению проблемы. Болезни и антибиотики 2012; (1): 31–46.

Thomson K.S., Moland E.S. Cefepime, piperacillin tazobactam, and the inoculum effect in tests with extended spectrum beta lactamase producing Enterobacteriaceae. Antimicrob. Agents Chemother. 2001; 45 (12): 3548–54.

Harris P.N., Tambyah P.A., Paterson D.L. в Lactam and β-lactamase inhibitor combina tions in the treatment of extended spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect. Dis. 2015; 15: 475–85.

Paterson D.L. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended spectrum beta lactamases (ESBLs). Clin. Microbiol. Infect. 2000; 6 (9): 460–3.

Rodriguez Bano J., Navarro M.D., Retamar P., et al. beta Lactam/beta lactam inhibitor combinations for the treatment of bacteremia due to extended spectrum beta lactamase producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin. Infect. Dis. 2012; 54: 167–74.

Chaubey V.P., Pitout J.D., Dalton B., et al. Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae. BMC Res. Notes 2010; 3: 116.

Lim Y.K., Lee M. K., Kim T. H. Management of extended spectrum beta lactamase positive gram negative bacterial urologic infections. Urogenit. Tract. Infect. 2015; 10 (2): 84–91.

Queenan A.M., Bush K. Carbapenemases: the versatile beta lactamases. Clin. Microbiol. Rev. 2007; 20: 440–58.

Patel G., Huprikar S., Factor S.H., et al. Outcomes of carbapenem resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect. Contr. Hosp. Epidemiol 2008; 29 (12): 1099–1106.

Yamamoto M., Pop Vicas A.E. Treatment for infections with carbapenem resistant Enterobacteriaceae: what options do we still have? Crit. Care 2014, 18: 229.

Hirsch E.B., Tam V.H. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug resistant infection. J. Antimicrob. Chemother. 2010; 65: 1119–25.

Paul M., Carmeli Y., Durante Mangoni E., et al. Combination therapy for carbapenem resistant Gram negative bacteria. J. Antimicrob. Chemother. 2014; 69: 2305–9.

Karam G., Chastre J., Wilcox M.H., et al. Antibiotic strategies in the era of multidrug resistance. Crit. Care 2016; 20: 136.

Craig W.A. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta lactams, glycopeptides, and line zolid. Infect. Dis. Clin. North. Am. 2003; 17: 479–501.

Drusano G.L. Antimicrobial pharmacody namics: critical interactions of ‘bug and drug’. Nat. Rev. Microbiol. 2004; 2: 289–300.

McKinnon P.S., Paladino J.A., Schentag J.J. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int. J. Antimicrob. Agents 2008, 31: 345–351.

Tam V.H., Schilling A.N., Neshat S., et al. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2005, 49: 4920–4927.

Roberts J.A., Kruger P., Paterson D.L., et al. Antibiotic resistance – what’s dosing got to do with it? Crit. Care Med. 2008, 36: 2433–2440.

Chant C., Leung A., Friedrich J.O. Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta analysis. Crit. Care 2013, 17: R279.

Bodmann K. F., Grabein B., Expert Commission of the Paul Ehrlich Society for Chemotherapy e.V. Recommendations for empiric parenteral initial antibiotic therapy of bacterial diseases in adults: Update 2010. GMS Infect. Dis. 2014; 2: 1–101.

Tacconelli E., De Angelis G., Cataldo M.A., et al. Does antibiotic exposure increase the risk of methicillin resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta analysis. J. Antimicrob. Chemother. 2008; 61: 26–38.

Sedláková M.H., Urbánek K., Vojtová V., et al. Antibiotic consumption and its influence on the resistance in Enterobacteriaceae. BMC Research Notes 2014; 7: 454.

Nicolle L.E. Catheter related urinary tract infection. Drugs Aging. 2005; 22: 627–39.

Лямин А.В., Боткин Е.А., Жестков А.В. Проблемы в медицине, связанные с бактериальными пленками. Клин. микробиол. антимикроб. химиотер. 2012; 14 (4): 268–275.

Голуб А.В. Бактериальные биопленки – новая цель терапии? Клин. микробиол. антимикроб. химиотер. 2012; 14 (1): 23–29.

Чеботарь И.В., Маянский А.Н., Кончакова Е.Д., и др. Антибиотикорезистентность биоплёночных бактерий. Клин. микробиол. антимикроб. химиотер. 2012; 14 (1): 51–8.

Oyabu Y. [Clinical study on sulbactam/cefoperazone in urinary tract infections in elderly patients]. Jpn. J. Antibiot. 1996; 49 (3): 250–5.

Nakamura A., Himi K., Matsumura C., et al. [Clinical studies of sulbactam/cefopera zone therapy in pediatric bacterial infections]. Jpn. J. Antibiot. 1984;37 (10):1793–800.

Страчунский Л.С., Галкин Д.В., Козлов Р.С., исследовательская группа ИРИС. Эффективность цефоперазона/сульбактама при бактериальном сепсисе: результаты многоцентрового проспективного исследования «ИРИС». Клин. микробиол. антимикроб. химиотер. 2003; 5 (4): 318–328.